Controloc Control 20mg (14 Tablets)
CONTROLOC Control is indicated for the short-term treatment of symptoms of gastro-oesophageal reflux disease (e.g. heartburn, regurgitation) in adults.
Active substance: Pantoprazole
1 gastro-resistant tablet contains 20 mg of pantoprazole (as sodium pantoprazole
one and a half water).
For a full list of excipients, see section 6.1.
The recommended dose is 20 mg pantoprazole (1 tablet) once a day.
It may be necessary to use the medicine for another 2-3 days to obtain relief of symptoms. Treatment should be discontinued when symptoms have completely disappeared. Treatment should not exceed 4 weeks without consulting a doctor.
Patients should be instructed to consult a physician if symptoms persist within 2 weeks of treatment.
Special patient groups
No dosage adjustment is necessary in elderly patients or in patients with renal or hepatic impairment.
Children and youth
CONTROLOC Control should not be used in children and adolescents under 18 years of age due to limited data collected on safety and efficacy.
Method of administration
CONTROLOC Control 20 mg gastro-resistant tablets should not be chewed or crushed. They should be taken before a meal, swallowed whole with water.
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Co-administration with atazanavir (see section 4.5).
Al / Al blisters with or without cardboard reinforcement containing 14 gastro-resistant tablets.
The patient should contact a doctor in the event of:
• Weight loss not due to intentionally weight loss, anemia, gastrointestinal bleeding, dysphagia, persistent or bloody vomiting. Treatment with pantoprazole may alleviate the symptoms of a severe disease and delay diagnosis. In these cases, it is necessary to exclude the neoplastic origin of the disease.
• Have a history of gastric ulcer or gastrointestinal surgery.
• Relief of symptoms of indigestion or heartburn for a continuous period of more than 4 weeks.
• Jaundice, dysfunction or liver disease.
• Other serious illnesses affecting your general well-being.
• If you are over 55 years of age and have new symptoms or the nature of the symptoms you are already seeing has changed.
Patients with long-term, recurring symptoms of indigestion or heartburn should be monitored regularly. In particular, patients over 55 years of age using non-prescription indigestion or heartburn remedies on a daily basis should inform their doctor or pharmacist.
Patients should not use other proton pump inhibitors or histamine H 2 antagonists concurrently .
Patients who are due to have an endoscopy or urease test should consult their physician before taking this medicinal product.
Patients should be informed that the drug is not intended to relieve symptoms immediately. Symptoms may be relieved after approximately one day of pantoprazole use. You may need to use it for 7 days for complete heartburn relief. Patients should not take pantoprazole as a preventive measure.
Reducing gastric acidity, for whatever reason, including through the use of proton pump inhibitors, increases the amount of bacteria normally present in the gastrointestinal tract. The use of acid-reducing drugs leads to a slightly increased risk of gastrointestinal infections such as Salmonella , Campylobacter or C. difficile infection.
There are no adequate data on the use of pantoprazole in pregnant women. Animal studies have shown reproductive toxicity. There was no evidence of impaired fertility or teratogenicity in preclinical studies (see section 5.3). The potential risk for humans is unknown. CONTROLOC Control is contraindicated during pregnancy.
There are no data on the excretion of pantoprazole in human breast milk. Animal studies have shown excretion of pantoprazole in milk. CONTROLOC Control is contraindicated during breast-feeding.
Animal studies have shown no impairment of fertility following the administration of pantoprazole (see section 5.3).
CONTROLOC Control has no or negligible influence on the ability to drive and use machines.
Adverse drug reactions such as dizziness and visual disturbances may occur (see section 4.8). In such cases, patients should refrain from driving or operating machinery.
There are no known symptoms of overdose in humans.
Doses up to 240 mg administered intravenously over 2 minutes were well tolerated.
As pantoprazole is extensively bound to plasma proteins, it is difficult to dialysate.
In the event of an overdose with clinical signs of intoxication, apart from symptomatic and supportive treatment, no specific therapeutic recommendations can be made.
Interactions with other drugs
CONTROLOC Control may reduce the absorption of active substances whose bioavailability is dependent on the gastric pH (e.g. ketoconazole).
Co-administration of 300 mg atazanavir / 100 mg ritonavir with omeprazole (40 mg daily) or 400 mg atazanavir with lansoprazole (60 mg single dose) has been shown to significantly reduce the bioavailability of atazanavir to healthy volunteers. The absorption of atazanavir is pH dependent. Therefore, pantoprazole should not be co-administered with atazanavir (see section 4.3).
Pantoprazole is metabolised in the liver with the participation of the cytochrome P-450 enzyme system. An interaction of pantoprazole with other substances which are metabolised via the same enzyme system cannot be excluded. No clinically significant interactions were found in specific tests performed with: carbamazepine, caffeine, diazepam, diclofenac, digoxin, ethanol, glibenclamide, metoprolol, naproxen, nifedipine, phenytoin, piroxicam, theophylline and ethinylestradiol containing oral contraceptives.
Based on the pharmacokinetic studies performed, no interaction was found between pantoprazole and phenprocoumon or warfarin. However, after introducing the product to the market in individual cases, changes in the value of the international normalized ratio – INR were observed during their simultaneous use. Therefore, in patients treated with anticoagulants with coumarin derivatives (e.g. phenprocoumon or warfarin), it is recommended to monitor the prothrombin time (INR) after initiation, termination or during irregular use of pantoprazole.
In some patients it has been observed that the concomitant use of high doses of methotrexate (e.g. 300 mg) with proton pump inhibitors led to increased levels of methotrexate. Therefore, temporary discontinuation of proton pump inhibitors should be considered in patients on high doses of methotrexate, e.g. in cancer or psoriasis.
There were no interactions with concomitantly administered antacids.
Approximately 5% of patients are expected to experience side effects. The most frequently reported adverse reactions occurring in approximately 1% of patients are diarrhea and headache. The following side effects have been reported with pantoprazole.
In the table below, adverse reactions are ranked under the frequency classification
Very common (≥1 / 10); Common (≥1 / 100 to <1/10); Uncommon (≥1 / 1,000 to <1/100); Rare (≥1 / 10,000 to <1 / 1,000); Very rare (≤1 / 10,000), not known (cannot be estimated from the available data).
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Table No. 1. Adverse reactions with pantoprazole in clinical trials and post-marketing
|The frequency of occurrence
System organ classification
|Not so often||Rarely||Very rarely||Unknown|
|Blood and the lymphatic system disorders||Agranulocytosis||Thrombocytopenia;
|Nervous system disorders||Headaches;
|Eye disorders||Visual disturbance / blurred vision|
stomach and intestines
Nausea / vomiting;
A feeling of fullness in the abdomen
and flatulence; Constipation;
Dry mouth; Abdominal pain and discomfort
|Renal and tract disorders
|Skin and subcutaneous tissue disorders||Rash
skin / Erythema /
|Hives; Angioedema||Stevens-Johnson syndrome; Lyell’s syndrome; Erythema multiforme; Hypersensitivity to light|
musculoskeletal and connective tissues
|Metabolism and nutrition disorders||Hyperlipidemia and increased lipid levels (triglycerides, cholesterol);
|General disorders and conditions in||Weakness, fatigue and bad||Increase in body temperature;|
|application site||well-being||Edema peripheral|
|Immune system disorders||Hypersensitivity (including anaphylactic reactions
and anaphylactic shock)
liver and biliary tract
|Increased liver enzymes
|Increase in bilirubin||Damage
Jaundice; Liver cell failure
|Mental disorders||Sleep disturbance||Depression (and mental deterioration)||Confusion (and mental deterioration)||Hallucinations, confusion (especially in susceptible patients like
also the worsening of similar symptoms with them
|Reproductive system and breast disorders||Gynecomastia|